{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:17:42Z","timestamp":1785788262820,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI094586"],"award-info":[{"award-number":["R01AI094586"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Advances in biomedical HIV prevention will soon offer young women a choice of HIV prevention methods, including various pre-exposure prophylaxis (PrEP) modalities such as daily oral pills, dapivirine vaginal ring, and long-acting injectable agents. By understanding preferences for contraceptive methods, we may draw analogies for the HIV prevention needs of young women.<\/jats:p>\n                <jats:p>The UChoose Study was an open-label randomised cross-over study designed to evaluate the acceptability and preference for several contraceptive options as a proxy for HIV prevention methods that use similar types of administration. The study enrolled healthy HIV uninfected young women aged 15 to 19\u00a0years. At enrolment, participants were randomly assigned to a contraceptive method for a period of 16\u00a0weeks in the form of monthly Nuvaring\u00ae (vaginal ring), daily combined oral contraceptive (daily pills), or bi-monthly injectable contraceptive (injectable). After 16\u00a0weeks, participants crossed over to another contraceptive method, and those who had received the injectable and the daily pills received the vaginal ring for another 16\u00a0weeks, whereas those who had received the vaginal ring were able to choose between the injectable and daily pills, to ensure that all participants tried the vaginal ring\u2014the least familiar option to the study population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-three participants were purposively recruited to participate in seven focus group discussions (FGD) and completed a pre-survey for their assigned group. Our sample comprised 14 participants randomised to use of the vaginal ring and daily pills and 19 participants randomised to use of the vaginal ring and injectable. For most participants, their preferences for a prevention method were based primarily on their desire to avoid negative aspects of one method rather than their positive user experience with another method. Most participants expressed initial hesitancy for trying new contraception method products; however, a lack of familiarity was moderated by a strong interest in diverse user-controlled prevention methods. Participants valued methods that had infrequent dosing and simplified use requirements. The injection and vaginal ring were preferred over daily pills as a potential HIV prevention method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Expanding the availability of diverse products could provide adolescents with multiple choices in HIV prevention for the uninitiated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02404038\">NCT02404038<\/jats:ext-link>). Registered March 31, 2015\u2014Registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-023-16955-3","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T11:02:47Z","timestamp":1698922967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["\u201cIt\u2019s already in your body and it\u2019s preventing\u201d: a qualitative study of African female adolescent\u2019s acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-6747","authenticated-orcid":false,"given":"Lauren","family":"Fynn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millicent","family":"Atujuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menna","family":"Duyver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Ngcobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rinehart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybil","family":"Hosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"16955_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS. 2022. Retrieved 1 July 2022, from https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20151027_UNAIDS_PCB37_15_18_EN_rev1.pdf."},{"key":"16955_CR2","unstructured":"UNAIDS Data 2018. Geneva, Switzerland: Joint United Nations Programme on HIV\/AIDS (UNAIDS). 2018. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/unaids-data-2018_en.pdf."},{"key":"16955_CR3","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 Fact sheet. 2022. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"issue":"1","key":"16955_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12889-018-5208-0","volume":"18","author":"H Huerga","year":"2018","unstructured":"Huerga H, Van Cutsem G, Farhat JB, Puren A, Bouhenia M, Wiesner L, et al. Progress towards the UNAIDS 90\u201390-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey. BMC Public Health. 2018;18(1):303.","journal-title":"BMC Public Health"},{"issue":"6","key":"16955_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509\u201318.","journal-title":"N Engl J Med"},{"issue":"10013","key":"16955_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomized trial. The Lancet. 2016;387(10013):53\u201360.","journal-title":"The Lancet"},{"issue":"7","key":"16955_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/apc.2017.0075","volume":"31","author":"A van der Straten","year":"2017","unstructured":"van der Straten A, Shapley-Quinn MK, Reddy K, Cheng H, Etima J, Woeber K, et al. Favoring \u201cPeace of Mind\u201d: A qualitative study of African women\u2019s HIV prevention product formulation preferences from the MTN-020\/ASPIRE trial. AIDS Patient Care STDS. 2017;31(7):305\u201314.","journal-title":"AIDS Patient Care STDS"},{"issue":"7","key":"16955_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/apc.2017.0075","volume":"31","author":"A van der Straten","year":"2017","unstructured":"van der Straten A, Shapley-Quinn MK, Reddy K, Cheng H, Etima J, Woeber K, et al. Favoring \u201cPeace of Mind\u201d: A Qualitative Study of African Women\u2019s HIV Prevention Product Formulation Preferences from the MTN-020\/ASPIRE Trial. AIDS Patient Care STDs. 2017;31(7):305\u201314.","journal-title":"AIDS Patient Care STDs"},{"issue":"3","key":"16955_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1089\/apc.2019.0242","volume":"34","author":"SK Calabrese","year":"2020","unstructured":"Calabrese SK, Galvao RW, Dovidio JF, Willie TC, Safon CB, Kaplan C, et al. Contraception as a potential gateway to pre-exposure prophylaxis: US women\u2019s pre-exposure prophylaxis modality preferences align with their birth control practices. AIDS Patient Care STDS. 2020;34(3):132\u201346.","journal-title":"AIDS Patient Care STDS"},{"issue":"10","key":"16955_CR10","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s11136-006-0026-8","volume":"15","author":"H Colwell","year":"2006","unstructured":"Colwell H, Mathias S, Cimms T, Rothman M, Friedman A, Patrick D. The ORTHO BC-SAT\u2013a satisfaction questionnaire for women using hormonal contraceptives. Qual Life Res. 2006;15(10):1621\u201331.","journal-title":"Qual Life Res"},{"key":"16955_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/IJWH.S185712","volume":"11","author":"MK Shapley-Quinn","year":"2019","unstructured":"Shapley-Quinn MK, Manenzhe KN, Agot K, Minnis AM, van der Straten A. \u201cWe are not the same\u201d: african women\u2019s view of multipurpose prevention products in the TrIO clinical study. Int J Women\u2019s Health. 2019;11:97.","journal-title":"Int J Women's Health"},{"issue":"9639","key":"16955_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S0140-6736(08)60886-7","volume":"372","author":"TJ Coates","year":"2008","unstructured":"Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. The Lancet. 2008;372(9639):669\u201384.","journal-title":"The Lancet"},{"key":"16955_CR13","first-page":"179","volume":"11","author":"C Fernandez","year":"2019","unstructured":"Fernandez C, van Halsema CL. Evaluating cabotegravir\/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV\/AIDS (Auckland, NZ). 2019;11:179.","journal-title":"HIV\/AIDS (Auckland, NZ)"},{"issue":"8","key":"16955_CR14","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1007\/s10461-018-2078-5","volume":"22","author":"AM Minnis","year":"2018","unstructured":"Minnis AM, Roberts ST, Agot K, Weinrib R, Ahmed K, Manenzhe K, et al. Young women\u2019s ratings of three placebo multipurpose prevention technologies for HIV and pregnancy prevention in a randomized, cross-over study in Kenya and South Africa. AIDS Behav. 2018;22(8):2662\u201373.","journal-title":"AIDS Behav"},{"issue":"1","key":"16955_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10461-017-1911-6","volume":"22","author":"R Weinrib","year":"2018","unstructured":"Weinrib R, Minnis A, Agot K, Ahmed K, Owino F, Manenzhe K, et al. End-users\u2019 product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South Africa. AIDS Behav. 2018;22(1):133\u201345.","journal-title":"AIDS Behav"},{"issue":"3","key":"16955_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/QAI.0000000000000158","volume":"66","author":"AL Corneli","year":"2014","unstructured":"Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66(3):324.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"16955_CR17","volume-title":"Reasons for non-adherence to the dapivirine vaginal ring: results of the MTN-032\/AHA study. AIDS (London, England)","author":"ET Montgomery","year":"2018","unstructured":"Montgomery ET, Stadler J, Naidoo S, Katz A, Laborde N, Garcia M, et al. Reasons for non-adherence to the dapivirine vaginal ring: results of the MTN-032\/AHA study. AIDS (London, England). 2018."},{"issue":"3","key":"16955_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/sextrans-2017-053217","volume":"94","author":"K Yun","year":"2018","unstructured":"Yun K, Xu JJ, Zhang J, Li JM, Hu QH, Chu ZX, et al. Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV. Sexually Transm Infect. 2018;94(3):163\u20138.","journal-title":"Sexually Transm Infect"},{"issue":"5","key":"16955_CR19","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s10461-016-1458-y","volume":"21","author":"KR Amico","year":"2017","unstructured":"Amico KR, Wallace M, Bekker L-G, Roux S, Atujuna M, Sebastian E, et al. Experiences with HPTN 067\/ADAPT study-provided open-label PrEP among women in Cape Town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21(5):1361\u201375.","journal-title":"AIDS Behav"},{"issue":"1","key":"16955_CR20","doi-asserted-by":"publisher","first-page":"e28238","DOI":"10.1371\/journal.pone.0028238","volume":"7","author":"AB Eisingerich","year":"2012","unstructured":"Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV pre-exposure prophylaxis among potential user groups: a multinational study. PLoS One. 2012;7(1):e28238.","journal-title":"PLoS One"},{"issue":"10","key":"16955_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/09540121.2019.1587352","volume":"31","author":"KH Footer","year":"2019","unstructured":"Footer KH, Lim S, Rael CT, Greene GJ, Carballa-Di\u00e9guez A, Giguere R, et al. Exploring new and existing PrEP modalities among female sex workers and women who inject drugs in a US city. AIDS Care. 2019;31(10):1207\u201313.","journal-title":"AIDS Care"},{"issue":"5","key":"16955_CR22","doi-asserted-by":"publisher","first-page":"e25282","DOI":"10.1002\/jia2.25282","volume":"22","author":"R Glaubius","year":"2019","unstructured":"Glaubius R, Ding Y, Penrose KJ, Hood G, Engquist E, Mellors JW, et al. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. J Int AIDS Soc. 2019;22(5):e25282.","journal-title":"J Int AIDS Soc"},{"issue":"10","key":"16955_CR23","doi-asserted-by":"publisher","first-page":"e0204821","DOI":"10.1371\/journal.pone.0204821","volume":"13","author":"ND Laborde","year":"2018","unstructured":"Laborde ND, Leslie J, Krogstad E, Morar N, Mutero P, Etima J, et al. Perceptions of the \u201cFabric\u201d \u2013 An exploratory study of a novel multi-purpose technology among women in Sub Saharan Africa. PLoS One. 2018;13(10):e0204821.","journal-title":"PLoS One"},{"key":"16955_CR24","doi-asserted-by":"crossref","unstructured":"Giovenco D, Kuo C, Underhill K, Hoare J, Operario D. Adolescent-centered HIV prevention: perspectives on acceptability of oral antiretroviral pre-exposure prophylaxis for adolescents in a global priority setting.\u00a0Arch Sex Behav. 2021;50:2921\u201331.","DOI":"10.1007\/s10508-021-02052-2"},{"key":"16955_CR25","doi-asserted-by":"crossref","unstructured":"Goparaju L, Praschan NC, Warren-Jeanpiere L, Experton LS, Young MA, Kassaye S. Stigma, partners, providers and costs: potential barriers to PrEP uptake among US women.\u00a0J AIDS Clin Res. 2017;8(9).","DOI":"10.4172\/2155-6113.1000730"},{"issue":"5","key":"16955_CR26","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s10461-016-1627-z","volume":"21","author":"FM Koechlin","year":"2017","unstructured":"Koechlin FM, Fonner VA, Dalglish SL, O\u2019Reilly KR, Baggaley R, Grant RM, et al. Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2017;21(5):1325\u201335.","journal-title":"AIDS Behav"},{"issue":"10","key":"16955_CR27","doi-asserted-by":"publisher","first-page":"e25626","DOI":"10.1002\/jia2.25626","volume":"23","author":"K Gill","year":"2020","unstructured":"Gill K, Happel AU, Pidwell T, Mendelsohn A, Duyver M, Johnson L, et al. An open-label, randomized cross-over study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose). J Int AIDS Soc. 2020;23(10):e25626.","journal-title":"J Int AIDS Soc"},{"key":"16955_CR28","volume-title":"IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0","author":"Statistics I","year":"2013","unstructured":"Statistics I. IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk: IBM Corp. Google Search; 2013."},{"key":"16955_CR29","unstructured":"Ritchie J, Lewis J, Nicholls CM, Ormston R, editors. Qualitative research practice: A guide for social science students and researchers. sage; 2013."},{"key":"16955_CR30","doi-asserted-by":"publisher","unstructured":"Edwards-Jones A. Qualitative Data Analysis with NVIVO.\u00a0J Educ Teach. 2014;40(2):193\u20135. https:\/\/doi.org\/10.1080\/02607476.2013.866724.","DOI":"10.1080\/02607476.2013.866724"},{"key":"16955_CR31","unstructured":"NVivo: version 11 - qualitative data analysis software. QSR International London; 2015."},{"issue":"1","key":"16955_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12889-018-5051-3","volume":"18","author":"M Mabaso","year":"2018","unstructured":"Mabaso M, Sokhela Z, Mohlabane N, Chibi B, Zuma K, Simbayi L. Determinants of HIV infection among adolescent girls and young women aged 15\u201324 years in South Africa: a 2012 population-based national household survey. BMC Public Health. 2018;18(1):183.","journal-title":"BMC Public Health"},{"issue":"8","key":"16955_CR33","doi-asserted-by":"publisher","first-page":"e25170","DOI":"10.1002\/jia2.25170","volume":"21","author":"EA Krogstad","year":"2018","unstructured":"Krogstad EA, Atujuna M, Montgomery ET, Minnis A, Ndwayana S, Malapane T, et al. Perspectives of South African youth in the development of an implant for HIV prevention. J Int AIDS Soc. 2018;21(8):e25170.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"16955_CR34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s40265-019-01143-8","volume":"79","author":"I Hodges-Mameletzis","year":"2019","unstructured":"Hodges-Mameletzis I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R. Pre-exposure prophylaxis for HIV prevention in women: current status and future directions. Drugs. 2019;79(12):1263\u201376.","journal-title":"Drugs"},{"issue":"3","key":"16955_CR35","doi-asserted-by":"publisher","first-page":"e25094","DOI":"10.1002\/jia2.25094","volume":"21","author":"A van der Straten","year":"2018","unstructured":"van der Straten A, Agot K, Ahmed K, Weinrib R, Browne EN, Manenzhe K, et al. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018;21(3):e25094.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"16955_CR36","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s10461-019-02521-9","volume":"24","author":"E Pleasants","year":"2020","unstructured":"Pleasants E, Tauya T, Reddy K, Mirembe B, Woeber K, Palanee-Phillips T, et al. Relationship type and use of the vaginal ring for HIV-1 prevention in the MTN 020\/ASPIRE trial. AIDS Behav. 2020;24(3):866\u201380.","journal-title":"AIDS Behav"},{"key":"16955_CR37","doi-asserted-by":"publisher","first-page":"19146","DOI":"10.7448\/IAS.17.3.19146","volume":"17","author":"A van der Straten","year":"2014","unstructured":"van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17:19146.","journal-title":"J Int AIDS Soc"},{"key":"16955_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.addr.2015.02.004","volume":"92","author":"C Woodsong","year":"2015","unstructured":"Woodsong C, Holt JD. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy. Adv Drug Deliv Rev. 2015;92:146\u201354.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"16955_CR39","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s10461-012-0317-8","volume":"17","author":"EM Van der Elst","year":"2013","unstructured":"Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162\u201372.","journal-title":"AIDS Behav"},{"issue":"3","key":"16955_CR40","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1089\/aid.2017.0156","volume":"34","author":"A Zanolini","year":"2018","unstructured":"Zanolini A, Chipungu J, Vinikoor MJ, Bosomprah S, Mafwenko M, Holmes CB, et al. HIV self-testing in Lusaka Province, Zambia: acceptability, comprehension of testing instructions, and individual preferences for self-test kit distribution in a population-based sample of adolescents and adults. AIDS Res Hum Retroviruses. 2018;34(3):254\u201360.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"16955_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/09540121.2012.699672","volume":"25","author":"K Lorimer","year":"2013","unstructured":"Lorimer K, Kidd L, Lawrence M, McPherson K, Cayless S, Cornish F. Systematic review of reviews of behavioural HIV prevention interventions among men who have sex with men. AIDS Care. 2013;25(2):133\u201350.","journal-title":"AIDS Care"},{"issue":"5","key":"16955_CR42","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/fampra\/cmz042","volume":"36","author":"SR Khare","year":"2019","unstructured":"Khare SR, Vedel I. Recall bias and reduction measures: an example in primary health care service utilization. Fam Pract. 2019;36(5):672\u20136. https:\/\/doi.org\/10.1093\/fampra\/cmz042.","journal-title":"Fam Pract"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-16955-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-16955-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-16955-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T11:03:07Z","timestamp":1698922987000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-16955-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["16955"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-16955-3","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Cape Town (UCT) Health Science Research Ethics Committee (720\/2014), the US National Institutes of Health, NIAID Division of AIDS, and registered in the public registry database of ClinicalTrials.gov (NCT02404038). Informed consent was obtained from all individual participants included in the study. The study adhered to the principles outlined in the Declaration of Helsinki for ethical research involving human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"By agreeing to be a part of this study during informed consent, all study participants agreed to have data collected from them and published anonymously.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AR is an employee of Viiv Healthcare. Viiv Healthcare funded the study. Nuvarings were donated to the project by MSD. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2143"}}